Company Description
Invea Therapeutics is a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases, or IMIDs.
Our aim is to develop oral, safe and effective small molecule therapies that control inflammation, prevent tissue damage, improve quality of life and achieve long-term disease remission.
Our drug discovery and development approach combines artificial intelligence and machine learning with our team’s extensive experience and expertise, to decode the mechanisms and pathways that drive the initiation and progression of inflammation for patients with IMIDs.
We currently have two product candidates, INVA8001, which we plan to progress into Phase 2b of clinical development, and INVA8003, which is in early stage preclinical development.
We believe that our product candidates, INVA8001 and INVA8003, if approved, can potentially transform the treatment of several IMIDs, such as atopic dermatitis and chronic urticaria which are characterized by limited or no available therapeutic options or patient populations that are unresponsive, partially responsive or develop resistance to currently available therapies.
| Country | United States |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Krishnan Nandabalan, Ph.D. |
Contact Details
Address: 2614 Boston Post Road, Suite 33AR Guilford, CT 06437 United States | |
| Phone | (203) 643-8060 |
| Website | inveatx.com |
Stock Details
| Ticker Symbol | INAI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001906425 |
| Employer ID | 87-3198325 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Krishnan Nandabalan, Ph.D. | Chairman, Chief Executive Officer, President |
| Shunichiro (Steve) Okada, M.D. | Chief Medical Officer |
| Salvatore Alesci, M.D., Ph.D. | Chief Scientific Officer |
| Aman Kant | Chief Business Officer |
| Michael J. Aiello | Chief Financial Officer |
| Kerrie Brady, BPharm, M.S., M.B.A. | Director |
| Jason Fenton | Director |
| Demetrios Kydonieus, J.D., M.B.A. | Director |
| Jonathan Zalevsky, Ph.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2025 | D | Notice of Exempt Offering of Securities |
| Mar 29, 2024 | RW | Filing |
| Jan 26, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 12, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Oct 20, 2023 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Oct 4, 2023 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Sep 15, 2023 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Aug 7, 2023 | DRS | [Cover] Draft Registration Statement |
| Apr 22, 2022 | D | Notice of Exempt Offering of Securities |